Latest News

MEDICAL NEWS
POSTED BY PULMONARY FIBROSIS FOUNDATION ON 8/29/2011

Actelion Pharmaceuticals Ltd / Actelion reports results of exploratory study with macitentan in IPF patients - promising long-term safety and tolerability profile - efficacy data not supportive of Phase III in IPF . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement.